Caution: Replication lag is high, changes newer than 1 hour may not be shown.
Top edits to an page
All edits made to a page by one user, in chronological order.
Page | Oncolytic virus (Log · Page History) |
User | Rod57 (Edit Counter· Top Edits) |
Total edits | 47 |
Minor edits | 18 (38.3%) |
(Semi-)automated edits | 0 (0%) |
Reverted edits | 0 (0%) |
atbe1 | 51.4 |
Added (bytes)2 | 7,534 |
Deleted (bytes) | -3,006 |
Minor edits
·
18 (38.3%)
Major edits
·
29 (61.7%)
(Semi-)automated edits
·
0 (0%)
Manual edits
·
47 (100%)
Reverted edits
·
0 (0%)
Unreverted edits
·
47 (100%)
1 Average time between edits (days)
2 Added text is any positive addition that wasn't reverted (approximate)
Date | Links | Size | Edit summary |
---|---|---|---|
2017-07-08 09:42 | Diff · History | 372 | →Clinical research: Note ONCOS-102 in ph 2 |
2016-10-15 18:18 | Diff · History | 11 | →Approved therapeutic agents: virus]] |
2016-10-15 17:42 | Diff · History | 110 | →Tumour targeting: {{further information|Oncolytic adenovirus}} & move {{further information |
2016-07-07 22:40 | Diff · History | 476 | →Started phase I: *ONCOS-102 is an engineered human serotype 5/3 adenovirus coding for human GM-CSF ... <ref |
2016-03-14 02:19 | Diff · History | 4 | →Started phase I: [[ |
2016-02-15 20:46 | Diff · History | 500 | ===Other=== The maraba virus, first identified in Brazilian sandflies, is being tested clinically.<ref & fix/swap section/subsection |
2016-02-12 11:55 | Diff · History | 269 | →Started phase I: *DNX-2401 is an oncolytic adenovirus with US Orphan drug status for glioma.<ref |
2016-02-12 11:51 | Diff · History | -536 | →Approved therapeutic agents: trim out of date text |
2016-02-05 02:42 | Diff · History | 116 | →Clinical research: ===Started phase III=== etc - most need updates |
2016-02-05 02:30 | Diff · History | 46 | →Oncolytic immunotherapy: Others in clinical trials include JX-594. |
2016-02-05 02:25 | Diff · History | 248 | →Possible applications: ===Oncolytic immunotherapy=== |
2016-02-05 02:17 | Diff · History | 2 | ==Oncolytic viruses in conjunction with existing cancer therapies== Move further down article to fit |
2016-02-05 02:15 | Diff · History | 403 | →Clinical research: split out : ==Approved therapeutic agents== now T-VEC approved |
2016-02-05 02:12 | Diff · History | 51 | →Oncolytic viruses in conjunction with existing cancer therapies: ===Pre-clinical research=== |
2015-12-17 14:54 | Diff · History | 4 | →Directed evolution: [[ |
2014-11-15 15:16 | Diff · History | 32 | →top: (OncoVex, T-VEC) recently (Jan 2012) , [[ |
2014-10-17 22:46 | Diff · History | 13 | →Clinical research: Move less developed ones further down section, [[ |
2012-12-16 02:27 | Diff · History | -79 | →Clinical research: remove personnel detail and combine the 2 JX-594 lines |
2012-12-16 02:22 | Diff · History | 4 | →Possible applications: [[ |
2011-07-15 10:03 | Diff · History | 646 | →Clinical research: cavatek ref for phase II |
2011-07-15 09:44 | Diff · History | 148 | →Clinical research: [[, <ref |
2011-05-12 15:12 | Diff · History | 329 | →Clinical research: REOLYSIN news etc |
2011-05-12 15:05 | Diff · History | 46 | →Clinical research: H101=oncorine |
2011-05-12 15:00 | Diff · History | 278 | →Clinical research: resolyn ref and oncorine |
2011-05-12 14:56 | Diff · History | 45 | →Clinical research: TNF gene therapy |
2011-05-12 14:40 | Diff · History | 186 | →Possible applications: ct ref |
2011-05-12 14:35 | Diff · History | 3 | →Immune response: // {{fact |
2011-05-12 14:30 | Diff · History | -235 | →Possible applications: rm purple/advocay prose |
2011-05-12 14:24 | Diff · History | 116 | →Possible applications: ref & [[ |
2011-01-27 13:47 | Diff · History | 17 | →Possible applications: {{fact|Jan 2009}} |
2010-11-25 12:34 | Diff · History | 11 | →Clinical research: [[GM-CSF| |
2010-11-25 12:33 | Diff · History | 22 | →Clinical research: (Ad5/3-D24-GMCSF) |
2010-11-25 12:07 | Diff · History | 414 | →Clinical research: *TNFerade failed a phase III trial for pancreatic cancer.<ref> |
2010-11-25 11:24 | Diff · History | 8 | →Possible applications: {{fact |
2010-11-25 11:21 | Diff · History | 23 | →History: H101 |
2010-11-25 11:17 | Diff · History | 8 | →Possible applications: [[ |
2010-11-25 11:15 | Diff · History | 1,136 | →Clinical research: paste in ====Oncolytic viruses in conjunction with existing cancer therapies==== + text from below |
2010-11-25 11:14 | Diff · History | -1,132 | →Oncolytic viruses in conjunction with existing cancer therapies: cut section to move up |
2010-11-25 11:08 | Diff · History | 43 | →Oncolytic viruses in conjunction with existing cancer therapies: ==See also== virotherapy |
2010-11-25 11:05 | Diff · History | 881 | →Possible applications: paste text from lower section as new ===Clinical research=== |
2010-11-25 11:03 | Diff · History | -889 | →Oncolytic viruses in conjunction with existing cancer therapies: cut to move up |
2010-11-25 11:02 | Diff · History | 19 | →Oncolytic viruses in conjunction with existing cancer therapies: GM-CSF]] (see above) |
2010-11-25 11:00 | Diff · History | -135 | →Possible applications: rm ad, {{fact |
2010-11-25 10:55 | Diff · History | 179 | →Oncolytic viruses in conjunction with existing cancer therapies: CGTG-102 ref |
2010-11-25 10:49 | Diff · History | 257 | →Oncolytic viruses in conjunction with existing cancer therapies: JX-584 should have been JX-594 - add refs & detail |
2010-11-25 10:36 | Diff · History | 19 | →Oncolytic viruses in conjunction with existing cancer therapies: Onyx-015 Abandoned in 2000. |
2010-11-25 10:32 | Diff · History | 39 | →Oncolytic viruses in conjunction with existing cancer therapies: {{fact, [[ |
All times are in UTC.